Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Feasibility and Optimal Schedule Of Using Eculizumab In Patients With Hemolytic Paroxysmal Nocturnal Hemoglobinuria (hPNH) With Severe Aplastic Anemia (SAA) Prior To Haemopoietic Stem Cell Transplant (HSCT)

Austin G Kulasekararaj, Victoria T Potter, MBBS, FRCPA, FRACP, Shreyans A Gandhi, MBBS, MD, Nana benson-Quarm, Joanna Large, RN, BSc, Antonio Pagliuca, MBBS, FRCP, FRCPath, MA, Ghulam J. Mufti, DM, FRCP, FRCPath, Judith Marsh

Blood (2013) 122 (21): 2482.

https://doi.org/10.1182/blood.V122.21.2482.2482

Published: 2013

Journal Articles

Somatic Mutations Implicated In Myeloid Malignancies Are Frequent In Idiopathic Aplastic Anaemia and Its Relevance To Disease Classification and Treatment- a Comprehensive Analysis Of 150 Patients

Jie Jiang, PhD, Austin G Kulasekararaj, Alexander E Smith, PhD, Azim M Mohamedali, PhD, Shreyans A Gandhi, MBBS, MD, Barbara Czepulkowski, BSc, Judith Marsh, Ghulam J. Mufti, DM, FRCP, FRCPath

Blood (2013) 122 (21): 803.

https://doi.org/10.1182/blood.V122.21.803.803

Published: 2013

Journal Articles

Eculizumab in Paroxysmal Nocturnal Hemoglobinuria (PNH): A Report of All 153 Patients Treated in the UK

Anita Hill, MBChB, PhD, Richard J Kelly, MBChB, Austin G Kulasekararaj, MBBS, MD, Shreyans A Gandhi, MBBS, MD, Lindsay D Mitchell, MBChB, Modupe Elebute, MBChB, MD, Stephen John Richards, PhD, Matthew Cullen, MSc, Louise M Arnold, RN, BSc, Joanna Large, RN, BSc, Alexandra Wood, RN, BSc, Gemma L Brooksbank, RN, BSc, Tracy Downing, Claire McKinley, BSc, Dena Cohen, BSc, MSc, Walter M Gregory, PhD, Judith C. W. Marsh, MD, PhD, Ghulam J. Mufti, MD, Peter Hillmen, MBChB, PhD

Blood (2012) 120 (21): 3472.

https://doi.org/10.1182/blood.V120.21.3472.3472

Published: 2012

Journal Articles

Alemtuzumab-Based RIC HSCT with Pre-Emptive DLI as An Effective Strategy to Achieve Long-Term Disease Remission In Patients with High Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukaemia (AML).

Shreyans A Gandhi, MBBS, MD, DNB, MRCP, Victoria T Potter, BSc, MBBS, Victoria J. Tindell, MBChB, Rachel Kesse-Adu, MBBS, Laura Reiff-Zall, Michelle Kenyon, Judith C. W. Marsh, MD, Aloysius Y Ho, Ghulam J. Mufti, DM, FRCP, FRCPath, Antonio Pagliuca, MBBS, FRCP, FRCPath, MA, ZiYi Lim, MD

Blood (2010) 116 (21): 1304.

https://doi.org/10.1182/blood.V116.21.1304.1304

Published: 2010

Journal Articles

Addition of Hydroxyurea to Transfusion Programme to Treat Progressive Cerebral Vasculopathy

Shreyans A Gandhi, MBBS, MD, DNB, MRCP, Apurva Mishra, Sue Height, Swee Lay Thein, Professor, David Rees

Blood (2010) 116 (21): 4813.

https://doi.org/10.1182/blood.V116.21.4813.4813

Published: 2010

NARROW

Feasibility and Optimal Schedule Of Using Eculizumab In Patients With Hemolytic Paroxysmal Nocturnal Hemoglobinuria (hPNH) With Severe Aplastic Anemia (SAA) Prior To Haemopoietic Stem Cell Transplant (HSCT)

Somatic Mutations Implicated In Myeloid Malignancies Are Frequent In Idiopathic Aplastic Anaemia and Its Relevance To Disease Classification and Treatment- a Comprehensive Analysis Of 150 Patients

Eculizumab in Paroxysmal Nocturnal Hemoglobinuria (PNH): A Report of All 153 Patients Treated in the UK

Alemtuzumab-Based RIC HSCT with Pre-Emptive DLI as An Effective Strategy to Achieve Long-Term Disease Remission In Patients with High Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukaemia (AML).

Addition of Hydroxyurea to Transfusion Programme to Treat Progressive Cerebral Vasculopathy

Email alerts

ASH Publications

American Society of Hematology

Feasibility and Optimal Schedule Of Using Eculizumab In Patients With Hemolytic Paroxysmal Nocturnal Hemoglobinuria (hPNH) With Severe Aplastic Anemia (SAA) Prior To Haemopoietic Stem Cell Transplant (HSCT)

Somatic Mutations Implicated In Myeloid Malignancies Are Frequent In Idiopathic Aplastic Anaemia and Its Relevance To Disease Classification and Treatment- a Comprehensive Analysis Of 150 Patients

Eculizumab in Paroxysmal Nocturnal Hemoglobinuria (PNH): A Report of All 153 Patients Treated in the UK

Alemtuzumab-Based RIC HSCT with Pre-Emptive DLI as An Effective Strategy to Achieve Long-Term Disease Remission In Patients with High Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukaemia (AML).

Addition of Hydroxyurea to Transfusion Programme to Treat Progressive Cerebral Vasculopathy

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only